These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 18722116)

  • 1. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
    Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 7. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
    Velázquez F; Venkatraman S; Blackman M; Pinto P; Bogen S; Sannigrahi M; Chen K; Pichardo J; Hart A; Tong X; Girijavallabhan V; Njoroge FG
    J Med Chem; 2009 Feb; 52(3):700-8. PubMed ID: 19154150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
    Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
    Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
    Bogen SL; Arasappan A; Velazquez F; Blackman M; Huelgas R; Pan W; Siegel E; Nair LG; Venkatraman S; Guo Z; Doll R; Shih NY; Njoroge FG
    Bioorg Med Chem; 2010 Mar; 18(5):1854-65. PubMed ID: 20149666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
    Lemon SM; Yi M; Li K
    Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
    [No Abstract]   [Full Text] [Related]  

  • 19. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
    Chen KX; Nair L; Vibulbhan B; Yang W; Arasappan A; Bogen SL; Venkatraman S; Bennett F; Pan W; Blackman ML; Padilla AI; Prongay A; Cheng KC; Tong X; Shih NY; Njoroge FG
    J Med Chem; 2009 Mar; 52(5):1370-9. PubMed ID: 19196021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.